15 Biggest Mid-Day Losers For Tuesday

Acorda Therapeutics Inc ACOR shares dipped 27 percent to $18.77 after the company reported that it has received a Refusal to File letter from the FDA for INBRIJA regarding its previously filed NDA.
Finish Line Inc FINL shares tumbled 19.6 percent to $8.38 after the company issued weak forecast for the second quarter and lowered its guidance for the year. The company also disclosed that its board has adopted a shareholder rights plan. FBR Capital downgraded Finish Line from Buy to Neutral, while Buckingham Research downgraded the stock from Neutral to Underperform.
J.Jill Inc JILL shares dropped 15.5 percent to $9.91. J.Jill posted in-line Q2 earnings, but issued a weak outlook.
CGG SA (ADR) CGG shares dropped 13.8 percent to $5.20 after tumbling 9.30 percent on Monday.
Root9B Holdings Inc RTNB shares declined 11.5 percent to $2.31 after dipping 12.71 percent on Monday.
Best Buy Co Inc BBY shares declined 10.5 percent to $55.90. Best Buy reported upbeat results for its second quarter and issued a strong forecast for the current quarter.
Valeant Pharmaceuticals Intl Inc VRX fell 8 percent to $13.10. Mizuho lowered its price target on Valeant from $8 to $7.
Fusion Telecommunications Int'l, Inc. FSNN shares dropped 7 percent to $2.13.
Intellia Therapeutics Inc NTLA declined 7 percent to $19.38. Chardan Capital downgraded Intellia Therapeutics from Buy to Neutral.
Helios and Matheson Analytics Inc HMNY shares dipped 6.4 percent to $3.06.
Mesoblast limited (ADR) MESO shares dropped 6.2 percent to $6.09.
Fang Holdings Ltd SFUN shares fell 6.1 percent to $3.40. SouFun Holdings reported a Q2 loss of $2.1 million on revenue of $110.1 million.
Helen of Troy Limited HELE declined 6 percent to $91.05. Bank of America initiated coverage on Helen of Troy with an Underperform rating.
Christopher & Banks Corporation CBK shares fell 4.1 percent to $1.40. Christopher & Banks posted a Q2 loss of $0.20 per share on revenue of $86.6 million.
AveXis Inc AVXS dropped 4.1 percent to $93.07. Nomura initiated coverage on AveXis with a Reduce rating.

Market News and Data brought to you by Benzinga APIs